Prevention of urinary tract toxicity of oxazaphosphorines (the active components of Ifosfamide, Cyclophosphamide , Trofosfamide) in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, Cyclophosphamide or Trofosfamide, urinary passage diseases in anamnesis.